[
  {
    "objectID": "Workpackage1.html",
    "href": "Workpackage1.html",
    "title": "Workpackage 1",
    "section": "",
    "text": "In this package we will establishing the quantitative relationship of Tpos and KPC- cabrapenemase producing Klebsiella pneumoniae inoculum in blood culture bottles.  The methods for the assay are a modification of those originally proposed by Kaltsas et al.1 Detailed procedures can be found at this link. Methodology for preparing the test inoculum was adapted from CLSI M21A and M26A guidelines.2,3\n\nBriefly, tubes containing 1.8 mL of pooled healthy human serum are inoculated with 0.2 mL of a series of ten-fold dilutions (5x101 to 5x107 CFU/mL) of the standardised inoculum of each test indicator strains.\nThe sera were are then transferred into BacT⁄ALERT bottles without antibiotic inactivating matrix (Biomérieux Inc) for aerobic incubation for 24 hours and monitored for time to positivity.\nTpos results were used to establish preliminary assay quality control ranges by testing in triplicate for five KPC-carbapenemase producing K. pneumoniae strains (KPC A, B and C strains; NDM, and VIM producing strains) and a reference K. pneumoniae ATCC strain producing ESBL enzyme only. More detailed information on the isolates can be found on the Protocols section.\nWe also compared how Tpos results change if the organism suspension prepared in phosphate buffered saline (PBS-0.9%) versus pooled human serum (serum).\n\n\n\n\nThe relationship between Tpos and the K. pneumoniae inoculum is shown in Figure 1 a linear relationship was observed from approximately 101-108 K. pneumoniae CFU/mL and a Tpos measured from 10.5 hours-4.5 hours over the tested inoculum range, with R2 of 0.92-0.94. The linear relationship of Tpos versus inoculum was consistent if the inoculum was prepared in PBS or pooled human serum as shown in Table 1.\n\n\n\n\n\n\nNote\n\n\n\nIn the original methodology proposed by Kaltsas et al,1 the isolate inoculum was reported as the inoculum introduced into the bottle, which already contains between 30-40 mL of growth media (depending on the manufacturer).\nTherefore we have followed this precedent of reporting the inoculum introduced into each bottle. This does not represent the final test inoculum that need to account for the total 42 mL volume in each bloodculture bottle.\nAll experiments were performed using bloodculture bottles without antibiotic inactivating matrix\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nwp1 <- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 <-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\nFigure 1: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nwp1 <- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\ndf <- data.frame (wp1)\ntable1<-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%>%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 1:  Effect of inoculum diluent on Tpos \n \n  \n    diluent \n    b0 \n    b1 \n    Rsqr \n    Rsqr_adj \n    Std.Error \n  \n \n\n  \n    pbs \n    32.05074 \n    -2.564975 \n    0.9343070 \n    0.9336227 \n    1.110872 \n  \n  \n    serum \n    33.02361 \n    -2.840223 \n    0.9231703 \n    0.9216023 \n    1.210130 \n  \n\n\n\n\n\n\n\n\n\n\n\n\nThese data confirm that Tpos exhibits a wide dynamic range as a surrogate indicator for viable CFU/mL."
  },
  {
    "objectID": "Workpackage1.html#workpackage-1b-effect-of-ceftazidimeavibactam-exposure-on-tpos",
    "href": "Workpackage1.html#workpackage-1b-effect-of-ceftazidimeavibactam-exposure-on-tpos",
    "title": "Workpackage 1",
    "section": "2 Workpackage 1B:  Effect of ceftazidime/avibactam exposure on Tpos",
    "text": "2 Workpackage 1B:  Effect of ceftazidime/avibactam exposure on Tpos\nThis workpackage explores how ceftazidime/avibactam concentrations, alone or in combination with other antibiotics alters Tpos for a standard bacterial inoculum of 1x104 CFU/mL of Klebsiella pneumoniae. \n\n2.1 Methods\nThe effect of increasing fixed ceftazidime/avibactam (CAZ/AVI) concentrations (4:1) on Tpos was investigated at an inoculum of 1x104 CFU/mL of K. pneumoniae KPC_B (MIC 1 mg/L) and K. pneumoniae NDM producing isolate (negative control) Table 2. All experiments were performed in > 5 replicates with an incubation period of 24 hours.\n\n\n2.2 Ceftazidime-Avibactam\nAs shown in Figure 2, a marked increased in the Tpos for KPC_B from < 10 hrs to > 24 hrs when CAZ/AVI concentrations surpassed 1 mg/L. In contrast, the negative control KPC_NDM strain exhibited consistent Tpos < 10hr at all test concentrations with lack of antimicrobial activity. Trends in Tpos relative to antibiotic exposure were fitted by Loess.\n\n\n\n\n\n\nNote\n\n\n\nDrug concentrations reported in figures represent the concentration of antibiotic injected (1 mL) into the bottle- “simulating” the antibiotic concentrations that would be detected in the bloodstream. Hence, these concentrations do not reflect the final antibiotic test concentration per 42 mL.\n\n\n\n\nCode\nlibrary (ggplot2)\ntheme_set(theme_bw())\nceftaz <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_single/ceftazidime.csv\")\nggplot(ceftaz, aes(x=conc_s, y=tpos, color=isolate, shape=isolate)) + \n  geom_point(size=4, alpha = 0.7) + \n  geom_smooth(aes(linetype=isolate), method= loess, color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE ) +\nscale_x_log10(name=\"CAZ/AVI test conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n\n\n\n\nFigure 2: Effect of ceftazidime/aviactam concentrations on Tpos of K. pneumoniae\n\n\n\n\n\n\nTable 2: Isolates used for testing\n\n\n\n\n\n\n\nIsolate\nCarbapenemase enzyme\nCeftazidime/avibactam Etest MIC (mg/L)\n\n\n\n\nKlebsiella pneumoniae KPC- B\nKPC-3\n1\n\n\nKlebsiella pneumoniae NDM\nNDM-2\n>64\n\n\n\n\n\n2.2.0.1 KPC B isolate (MIC 1 mg/L) tested with commercial pharmaceutical formulation\n\nThe relationship between ceftazidime/avibactam concentrations and Tpos were analyzed by testing increasing concentrations of ceftazidime (0-8 mg/L) and avibactam (fixed ratio 4:1) using the commercial Avycaz (Zavicefta) formulation in at least 5 replicate experiments performed on separate days.\nBottles were incubated with 1x104 Klebsiella pneumoniae KPC-B strain and incubated at 37°C for 24 hours. Tpos positivity was registered using the BACTEC Alert/3D software\nTpos data versus ceftazidime/avibactam concentrations were then fit to a 4-parameter logistic regression model using the Dose-Response Data Analysis (DRDA) package to estimate PD endpoints.4 Regression results were extracted using the Broom5 and Kableextra6 packages.\nResults of the pharmacodynamic analysis are shown in Figure 3. Ceftazidime/avibactam exhibited a steep Tpos response from and EC50 of 2.10 (95% CI 2.08-2.12) to and EC90 2.39 (2.33-2.45). As shown in Table 3, the transitional portion of the dose-response curve occurred 1-dilution above the MIC (1 mg/L) that was determined by Etest.\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments shown in Figure 3 were performed using commercial CAZ/AVI pharmaceutical formulation not analytical powder. Concentrations plotted on the X axis indicate concentrations of ceftazidime (4:1 relative to avibactam) in tubes\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_4 <- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 <- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit4, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 3: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_4 <- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 <- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit4, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 3:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    73.66731 \n    71.92413 \n    75.41048 \n  \n  \n    0.25 \n    78.61720 \n    77.51043 \n    79.72397 \n  \n  \n    0.5 \n    83.89969 \n    83.05534 \n    84.74404 \n  \n  \n    0.75 \n    89.53712 \n    88.10788 \n    90.96636 \n  \n  \n    0.9 \n    95.55335 \n    93.12523 \n    97.98147 \n  \n  \n    0.95 \n    99.87460 \n    96.42020 \n    103.32901 \n  \n\n\n\n\n\n\n\n\n2.2.1 Inoculum effects on ceftazidime/avibactam targets with commercial pharmaceutical formulation\n\n2.2.1.1 KPC B isolate (MIC 1 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_5 <- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfit5 <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit5, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 4: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a high-inoculum\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfit5 <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit5, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 4:  Pharmacodynamic estimates for a high-inoculum \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    82.08148 \n    71.35951 \n    92.80344 \n  \n  \n    0.25 \n    117.28496 \n    109.48524 \n    125.08468 \n  \n  \n    0.5 \n    167.58667 \n    159.06133 \n    176.11201 \n  \n  \n    0.75 \n    239.46201 \n    222.24533 \n    256.67869 \n  \n  \n    0.9 \n    342.16357 \n    290.42168 \n    393.90546 \n  \n  \n    0.95 \n    436.16833 \n    240.82684 \n    631.50983 \n  \n\n\n\n\n\n\n\n\n\n2.2.1.2 KPC B isolate (MIC 1 mg/L) tested with analytical powder\n\nThe relationship between ceftazidime/avibactam concentrations and Tpos were repeated by testing increasing concentrations of ceftazidime (0-8 mg/L) and avibactam (fixed ratio 4:1) using the analytical grade powder instead of the commercial pharmaceutical formulation. Experiments were performed in at least 5 replicate experiments on separate days.\nBottles were incubated with 1x104 Klebsiella pneumoniae KPC-B strain and incubated at 37°C for 24 hours. Tpos positivity was registered using the BACTEC Alert/3D software\nTpos data versus ceftazidime/avibactam concentrations were then fit to a 4-parameter logistic regression model using the Dose-Response Data Analysis (DRDA) package to estimate PD endpoints.4 Regression results were extracted using the Broom5 and Kableextra6 packages.\nAs shown in Figure 5, ceftazidime/avibactam exhibited a steep Tpos response with increasing concentrations with an EC50 of 2.10 (95% CI 2.08-2.12) to and EC90 2.39 (2.33-2.45). The transitional portion of the dose-response curve occurred 1-dilution above the MIC (1 mg/L) determined using Etest strips Table 5.\n\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments shown in Figure 5 were performed using CAZ/AVI analytical grade powder at a fixed 4:1 ratio. Concentrations plotted on the X axis indicate concentrations of ceftazidime (4:1 relative to avibactam) in tubes\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_6 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit6, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 5: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_6 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 <- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit6, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 5:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    68.88793 \n    61.14631 \n    76.62954 \n  \n  \n    0.25 \n    75.52374 \n    71.50425 \n    79.54322 \n  \n  \n    0.5 \n    82.79876 \n    79.85671 \n    85.74080 \n  \n  \n    0.75 \n    90.77456 \n    83.70890 \n    97.84023 \n  \n  \n    0.9 \n    99.51866 \n    86.97415 \n    112.06317 \n  \n  \n    0.95 \n    105.94237 \n    88.43755 \n    123.44720 \n  \n\n\n\n\n\n\n\n\n\n\n2.2.2 KPC A isolate (MIC 2 mg/L) tested with commercial formulation\n\nExperiments with the commercial and analytical powder forms of ceftazidime/avibactam were repeated substituting Klebsiella pneumoniae KPC A isolate (ceftazidime/avibactam MIC 2 mg/L).\nResults of the logistic regression analysis from studies with the commercial formulation demonstrated an EC50 4.14 mg/L (95% CI4.09-4.20) and an EC90 4.78 (95% CI 4.59-4.96) as shown in Figure 6. The transitional portion of the dose response curve occurred 1-dilution above the MIC of the isolate (2 mg/L) determined by Etest Table 6.\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments plotted in Figure 6 were performed using the commercial CAZ/AVI pharmaceutical formulation for K. pneumoniae KPC producing isolate A (MIC 2 mg/L)\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concencentrations to estiamted PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7 <- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 <- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit7, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 6: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7 <- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 <- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit7, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 6:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    143.5857 \n    138.9952 \n    148.1763 \n  \n  \n    0.25 \n    154.0912 \n    151.7888 \n    156.3936 \n  \n  \n    0.5 \n    165.3653 \n    163.4974 \n    167.2333 \n  \n  \n    0.75 \n    177.4643 \n    172.9862 \n    181.9424 \n  \n  \n    0.9 \n    190.4485 \n    183.1369 \n    197.7601 \n  \n  \n    0.95 \n    199.8183 \n    190.5343 \n    209.1023 \n  \n\n\n\n\n\n\n\n\n\n2.2.3 KPC A isolate (MIC 2 mg/L) tested with analytical powder\n\nSimilar experiments were performed using the same methodology and analytical grade powder of ceftazidime-avibactam formulation (fixed 4:1 ratio) against Klebsiella pneumoniae KPC A isolate (ceftazidime/avibactam MIC 2 mg/L).\nResults of the logistic regression are shown in Figure 7 and demonstrated an EC50 4.55 mg/L (95% CI4.29-4.83) and an EC90 6.89 (95% CI 5.71-8.08) shown in Table 7. The transitional portion of the dose response curve was relatively broader and occurred 1-3 dilutions above the MIC of the isolate (2 mg/L) determined by Etest.\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments reported in Figure 7 performed using pure powder at a CAZ:AVI ratio of 4:1\n\n\n\n\nCode\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_8 <- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 <- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit8, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 7: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_8 <- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 <- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit8, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 7:  Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    125.7716 \n    114.3869 \n    137.1562 \n  \n  \n    0.25 \n    143.8460 \n    136.1835 \n    151.5085 \n  \n  \n    0.5 \n    164.5179 \n    158.8981 \n    170.1377 \n  \n  \n    0.75 \n    188.1605 \n    179.1859 \n    197.1350 \n  \n  \n    0.9 \n    215.2007 \n    197.7571 \n    232.6444 \n  \n  \n    0.95 \n    235.7798 \n    202.9734 \n    268.5861 \n  \n\n\n\n\n\n\n\n\n\n\n\n2.3 Impact of testing fixed avibactam concentrations on pharmacodynamic estimates\n\n2.3.0.1 KPC A isolate (MIC 2 mg/L)\n\nWe further explored how the results would change if a single fixed concentration of avibactam (4 mg/L) was used in all tubes. Experiments were performed as described previously using the same method and the analytical-grade powder of ceftazidime-avibactam formulation with at fixed avibactam concentrations against Klebsiella pneumoniae KPC B isolate (ceftazidime/avibactam MIC 1 mg/L).\nResults of the logistic regression are shown in Figure 8 demonstrated a lower EC50 4.14 mg/L (95% CI 4.09-4.19 ) and an EC90 4.77 (95% CI 4.59-4.96) as shown in Table 8. The transitional portion of the dose response curve was relatively broader but occurred 1-3 dilutions near the MIC of the isolate (2 mg/L) determined by Etest.\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments performed in Figure 8 utilized pure powder with a fixed avibactam concentration of 4 mg/L in all ceftazidime containing bottles.\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_9 <- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 <- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit9, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 8: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_9 <- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 <- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit9, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 8:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.02302 \n    22.05197 \n    29.99406 \n  \n  \n    0.25 \n    37.21041 \n    34.05205 \n    40.36876 \n  \n  \n    0.5 \n    53.20729 \n    50.04995 \n    56.36463 \n  \n  \n    0.75 \n    76.08130 \n    70.56354 \n    81.59905 \n  \n  \n    0.9 \n    108.78892 \n    81.37114 \n    136.20669 \n  \n  \n    0.95 \n    138.74444 \n    47.74622 \n    229.74266 \n  \n\n\n\n\n\n\n\n\n\n2.3.0.2 KPC B isolate (MIC 1 mg/L)\n\nSimilar experiments were repeated with the Klebsiella pneumoniae KPC B isolate (ceftazidime/avibactam MIC 1 mg/L).\nResults of the logistic regression are shown in Figure 9 and demonstrated a lower EC50 1.28 mg/L (95% CI 1.18-1.38) and an EC90 2.66 (95% CI 1.87-3.44) shown in Table 9. The transitional portion of the dose response curve was relatively broader but occurred 1-3 dilutions near the MIC of the isolate (1 mg/L) determined by Etest.\n\n\n\n\n\n\n\nNote\n\n\n\nExperiments shown in Figure 9 were repeated using pure powder but with a fixed concentration of avibactam at 4 mg/L in all tubes\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_10 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10<- drda(tpos ~ ctz_s, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit10, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 9: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_10 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10 <- drda(tpos ~ ctz, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit5, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 9:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    82.08148 \n    71.35951 \n    92.80344 \n  \n  \n    0.25 \n    117.28496 \n    109.48524 \n    125.08468 \n  \n  \n    0.5 \n    167.58667 \n    159.06133 \n    176.11201 \n  \n  \n    0.75 \n    239.46201 \n    222.24533 \n    256.67869 \n  \n  \n    0.9 \n    342.16357 \n    290.42168 \n    393.90546 \n  \n  \n    0.95 \n    436.16833 \n    240.82684 \n    631.50983 \n  \n\n\n\n\n\n\n\n\n2.3.1 Summary of ceftazidime-avibactam experiments\nOverall these data show Tpos is a robust PD endpoint and the relationship of ceftazidime/avibactam concentrations versus Tpos follows classical sigmoidal dose response relationship with a steep transitional portion of the dose response curve that occurs near the MIC of the pathogen. Although ED50/90 estimates were broadly similar if the commercial (pharmaceutical) and analytical powder formulations were tested, used of high-fixed concentrations of avibactam or testing at very high K. pneumoniae inocula resulted in broader concentration-effect curves and higher EC50/90 estimates\n\n\n\n\n2.4 Meropenem\n\n2.4.0.1 ATCC isolate (MIC 0.03 mg/L)\n\nThe impact of increasing meropenem concentrations on Tpos observed with the ATCC ESBL producing Klebsiella pneumoniae was tested using similar methodology as previously described\nAnalytical powder was used to produce serum concentration\nAs shown in Figure 10 , Tpos increased as meropenem concentrations surpassed the MIC, with an estimated pharmacodynamic parameters consistent with previous experiments that showed transition in the EC50/EC90 at simulated serum concentrations near the MIC as shown in Table 10.\n\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero <- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 10: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero <- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 10:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    1.165027 \n    1.026833 \n    1.303220 \n  \n  \n    0.25 \n    1.460430 \n    1.351831 \n    1.569029 \n  \n  \n    0.5 \n    1.830736 \n    1.764894 \n    1.896577 \n  \n  \n    0.75 \n    2.294935 \n    2.177266 \n    2.412605 \n  \n  \n    0.9 \n    2.876837 \n    2.586027 \n    3.167648 \n  \n  \n    0.95 \n    3.354810 \n    2.861582 \n    3.848038 \n  \n\n\n\n\n\n\n\n\n2.4.0.2 KPC B isolate (MIC X?)\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero2 <- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 11: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero2 <- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 11:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    39.27741 \n    38.19835 \n    40.35648 \n  \n  \n    0.25 \n    40.68575 \n    39.82820 \n    41.54329 \n  \n  \n    0.5 \n    42.14458 \n    41.17684 \n    43.11232 \n  \n  \n    0.75 \n    43.65572 \n    42.30388 \n    45.00756 \n  \n  \n    0.9 \n    45.22105 \n    43.33285 \n    47.10925 \n  \n  \n    0.95 \n    46.31764 \n    43.91272 \n    48.72257 \n  \n\n\n\n\n\n\n\n\n\n\n2.5 Gentamicin\n\n2.5.0.1 KPC A isolate (MIC 2 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent1 <- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 <- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit12, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 12: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent1 <- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 <- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit12, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 12:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    56.65250 \n    53.43037 \n    59.87462 \n  \n  \n    0.25 \n    62.53591 \n    60.25523 \n    64.81660 \n  \n  \n    0.5 \n    69.03033 \n    67.01957 \n    71.04109 \n  \n  \n    0.75 \n    76.19920 \n    73.71019 \n    78.68821 \n  \n  \n    0.9 \n    84.11256 \n    79.42354 \n    88.80158 \n  \n  \n    0.95 \n    89.95932 \n    78.37830 \n    101.54033 \n  \n\n\n\n\n\n\n\n\n2.5.0.2 KPC B isolate (MIC 0.5 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent2 <- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 <- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit13, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 13: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent2 <- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 <- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit13, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 13:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    18.56332 \n    16.93133 \n    20.19530 \n  \n  \n    0.25 \n    19.92766 \n    19.06150 \n    20.79382 \n  \n  \n    0.5 \n    21.39227 \n    20.34817 \n    22.43636 \n  \n  \n    0.75 \n    22.96452 \n    20.81244 \n    25.11660 \n  \n  \n    0.9 \n    24.65233 \n    21.10862 \n    28.19605 \n  \n  \n    0.95 \n    25.87062 \n    20.96263 \n    30.77861 \n  \n\n\n\n\n\n\n\n\n\n\n\n2.6 Colistin\n\n2.6.1 KPC B isolate (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to colistin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncoli1 <- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 <- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Colistin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 14: Pharmacodynamic relationship of Tpos to colistin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncoli1 <- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 <- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 14:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    3.814341 \n    3.374386 \n    4.254296 \n  \n  \n    0.25 \n    4.696574 \n    4.395993 \n    4.997155 \n  \n  \n    0.5 \n    5.782863 \n    5.463324 \n    6.102402 \n  \n  \n    0.75 \n    7.120404 \n    6.500514 \n    7.740293 \n  \n  \n    0.9 \n    8.767309 \n    7.696486 \n    9.838132 \n  \n  \n    0.95 \n    10.100091 \n    8.130500 \n    12.069682 \n  \n\n\n\n\n\n\n\n\n\n\n2.7 Meropenem-vaborbactam\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem-vaborbactam concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nvabo1 <- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 <- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Meropenem-vabobactam serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 15: Pharmacodynamic relationship of Tpos to meropenem-vaborbactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nvabo1 <- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 <- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 15:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    5.391292 \n    4.092373 \n    6.690211 \n  \n  \n    0.25 \n    7.797856 \n    6.671079 \n    8.924633 \n  \n  \n    0.5 \n    11.278661 \n    10.098053 \n    12.459269 \n  \n  \n    0.75 \n    16.313228 \n    13.817427 \n    18.809029 \n  \n  \n    0.9 \n    23.595123 \n    18.006802 \n    29.183445 \n  \n  \n    0.95 \n    30.327549 \n    19.089870 \n    41.565227 \n  \n\n\n\n\n\n\n\n\n\n2.8 Tigecycline\n\n2.8.1 K. pneumonia KPC-A (MIC 0.75 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig1 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 <- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit15, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 16: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig1 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 <- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit15, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 16:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.21193 \n    22.64088 \n    29.78298 \n  \n  \n    0.25 \n    33.33312 \n    30.73822 \n    35.92801 \n  \n  \n    0.5 \n    42.38896 \n    40.56986 \n    44.20806 \n  \n  \n    0.75 \n    53.90507 \n    50.72689 \n    57.08325 \n  \n  \n    0.9 \n    68.54984 \n    60.64442 \n    76.45527 \n  \n  \n    0.95 \n    80.72308 \n    56.72937 \n    104.71680 \n  \n\n\n\n\n\n\n\n\n2.8.2 K. pneumonia KPC-B (MIC 0.38 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig2 <- read_excel(\"datasets_single/kpcb_tig.xlsx\")\nfit16 <- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit16, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 17: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig2 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit16 <- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit16, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 17:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.21193 \n    22.64088 \n    29.78298 \n  \n  \n    0.25 \n    33.33312 \n    30.73822 \n    35.92801 \n  \n  \n    0.5 \n    42.38896 \n    40.56986 \n    44.20806 \n  \n  \n    0.75 \n    53.90507 \n    50.72689 \n    57.08325 \n  \n  \n    0.9 \n    68.54984 \n    60.64442 \n    76.45527 \n  \n  \n    0.95 \n    80.72308 \n    56.72937 \n    104.71680"
  },
  {
    "objectID": "Workpackage1.html#workpackage-1c-effect-of-combination-antimicrobial-exposure-on-tpos",
    "href": "Workpackage1.html#workpackage-1c-effect-of-combination-antimicrobial-exposure-on-tpos",
    "title": "Workpackage 1",
    "section": "3 Workpackage 1C: Effect of combination antimicrobial exposure on Tpos",
    "text": "3 Workpackage 1C: Effect of combination antimicrobial exposure on Tpos\n\n3.1 Methods\n\nThe activity of combination ceftazidime/avibactam (4 to 1 ratio from commercial formulation) plus gentamicin (0-4 mg/L) was tested against Klebsiella pneumonia KPCB strain in 5 replicate experiments using an array of test concentrations.\n\n\n\nTest array\n\n\nThe effect of the antibiotic combinations Tpos combination was analyzed using a Bliss Independence Model of drug interaction using a workflow described for the synergy analysis using the BIGL package.7\nThe first step of the fitting procedure analyzed marginal data only, i.e.-those observations within the experiment where one of the compounds is dosed at zero. For each compound the corresponding marginal doses are modelled using a 4-parameter logistic model\nThe marginal models will be estimated together using non-linear least squares estimation procedure. A simple sum-of-squared-residuals minimization driven by a default Nelder-Mead algorithm from optim minimizer was used.\nPresence of synergistic or antagonistic effects was formalized by means of the meanR and maxR test. meanR test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmaxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\n\n\n\n3.2 Results\n\n\n3.3 Ceftazidime-avibactam + gentamicin\n\nThe results shown in ?@fig-10 demonstrated that CTZ/AVI + gentamicin is broadly synergistic over the range of tested concentrations, with and average 4.29 hr increase (95% CI 2.65-6.46) in Tpos versus the predicted null interactive response of ceftazidime-avibactam and gentamicin alone.\n\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_gent_kpcb <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/caz_gent_kpcb.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit <- fitMarginals(caz_gent_kpcb, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"GENT\"))\nsummary(marginalFit)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime and gentamicin, minimum constrained at 9 hrs and maximum contrastined at 24 hours\nplot(marginalFit) + ggtitle(paste(\"Ceftazidime/Avibactam + Gentamicin\"))\nrs <- fitSurface(caz_gent_kpcb, marginalFit,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.0477 [2.2481, 4.007]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9764 2.0572 11.8957  Syn\n39.9_19.95    9.4952 5.8848 13.1056  Syn\n79.8_19.95    6.6173 2.5914 10.6432  Syn\n79.8_4.9875   9.3826 2.0492 16.7161  Syn\n79.8_9.975    8.9935 6.0041 11.9828  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\nCode\nplot(rs, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 18: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\n## mean R statistic evaluates how the test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmeanR_N <-fitSurface(caz_gent_kpcb, marginalFit, statistic=\"meanR\",CP=rs$CP, B.B=20, parallel = FALSE)\n\n# maxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\nmaxR_N <- fitSurface(caz_gent_kpcb, marginalFit,\n                     statistic = \"maxR\", CP = rs$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_B <- fitSurface(caz_gent_kpcb, marginalFit,\n                     statistic = \"maxR\", CP = rs$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_both <- rbind(summary(maxR_N$maxR)$totals,\n                   summary(maxR_B$maxR)$totals)\n\ncontour(maxR_B,\n         ## colorPalette = c(\"blue\", \"black\", \"black\", \"red\"),\n        main = paste0(\" Ceftazidime/Avibactam + Gentamicin\"),\n        scientific = TRUE, digits = 3, cutoff = cutoff)\n\nplotConfInt(maxR_B, color =\"effect-size\")\n\nrsh <- fitSurface(caz_gent_kpcb, marginalFit,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(15,87) = 22.8701 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2      absR p-value call\n19.95_19.95 19.95 19.9500  4.641679   1e-04  Syn\n39.9_19.95  39.90 19.9500 11.185995  <2e-16  Syn\n79.8_19.95  79.80 19.9500  8.325151  <2e-16  Syn\n79.8_4.9875 79.80  4.9875  4.136343 0.00111  Syn\n79.8_9.975  79.80  9.9750 10.250631  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   5   0    15\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.2336 [2.1092, 4.1451]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9765 3.1071 10.8459  Syn\n39.9_19.95    9.5042 6.8960 12.1125  Syn\n79.8_19.95    9.3826 6.3518 12.4135  Syn\n79.8_4.9875   9.3826 3.1616 15.6037  Syn\n79.8_9.975    8.9938 6.5390 11.4485  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\nCode\nrsb <- fitSurface(caz_gent_kpcb, marginalFit, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(15,87) = 17.7733 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2      absR p-value call\n19.95_19.95 19.95 19.9500  4.116661 0.00138  Syn\n39.9_19.95  39.90 19.9500 10.126517  <2e-16  Syn\n79.8_19.95  79.80 19.9500  4.000327 0.00231  Syn\n79.8_4.9875 79.80  4.9875  4.149137 0.00122  Syn\n79.8_9.975  79.80  9.9750 10.372249  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   5   0    15\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.0477 [2.1585, 4.0323]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9764 2.0906 11.8623  Syn\n39.9_19.95    9.4952 6.1100 12.8804  Syn\n79.8_19.95    6.6173 2.6989 10.5357  Syn\n79.8_4.9875   9.3826 1.6980 17.0673  Syn\n79.8_9.975    8.9935 5.9019 12.0850  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\n\n\n\nFigure 19: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 20: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 21: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\nThe activity of combination ceftazidime/avibactam (4 to 1 ratio from analytical powder) plus gentamicin was tested against Klebsiella pneumonia_KPC_A strain in 5 replicate experiments using the same methodology.\nResults are shown in ?@fig-11.\n\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_gent_kpca2 <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kpca_gent_caz.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit2 <- fitMarginals(caz_gent_kpca2, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"GENT\"))\nsummary(marginalFit2)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime and gentamicin, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit2) + ggtitle(paste(\"Ceftazidime/Avibactam + Gentamicin\"))\nrs2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.5514 [4.9162, 6.2709]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6045 4.4936  8.7154  Syn\n1.9_1.425   10.2930 2.9105 17.6755  Syn\n2.85_0.475  13.3292 6.4187 20.2398  Syn\n2.85_0.95   13.1710 8.1373 18.2046  Syn\n2.85_1.425   9.4954 2.1260 16.8648  Syn\n3.8_0.0095   7.7899 0.7970 14.7828  Syn\n3.8_0.0285   7.7899 0.7970 14.7828  Syn\n3.8_0.2375   7.2899 3.4309 11.1488  Syn\n3.8_0.475    7.5611 4.3937 10.7285  Syn\n3.8_0.95     7.6972 4.8569 10.5375  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\nCode\nplot(rs2, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 22: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\n## mean R statistic evaluates how the test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmeanR_N2 <-fitSurface(caz_gent_kpca2, marginalFit2, statistic=\"meanR\",CP=rs2$CP, B.B=20, parallel = FALSE)\n\n# maxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\nmaxR_N2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                     statistic = \"maxR\", CP = rs2$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_B2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                     statistic = \"maxR\", CP = rs2$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_both2 <- rbind(summary(maxR_N2$maxR)$totals,\n                   summary(maxR_B2$maxR)$totals)\n\ncontour(maxR_B2,\n         ## colorPalette = c(\"blue\", \"black\", \"black\", \"red\"),\n        main = paste0(\" Ceftazidime/Avibactam + Gentamicin\"),\n        scientific = TRUE, digits = 3, cutoff = cutoff)\n\nplotConfInt(maxR_B2, color =\"effect-size\")\n\nrsh2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh2)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(18,150) = 33.6972 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1     d2      absR p-value call\n1.9_0.95   1.90 0.9500 13.591463  <2e-16  Syn\n1.9_1.425  1.90 1.4250  5.561332   1e-05  Syn\n1.9_1.9    1.90 1.9000  4.861305   2e-05  Syn\n2.85_0.475 2.85 0.4750  7.732139  <2e-16  Syn\n2.85_0.95  2.85 0.9500 10.656374  <2e-16  Syn\n2.85_1.425 2.85 1.4250  5.561332   1e-05  Syn\n3.8_0.0095 3.80 0.0095  3.341910 0.01935  Syn\n3.8_0.0285 3.80 0.0285  3.341910 0.01935  Syn\n3.8_0.2375 3.80 0.2375  4.845663   2e-05  Syn\n3.8_0.475  3.80 0.4750  6.340654  <2e-16  Syn\n3.8_0.95   3.80 0.9500  7.681099  <2e-16  Syn\n3.8_1.9    3.80 1.9000  3.825904 0.00349  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  12   0    18\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.6804 [5.0922, 6.5342]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6547 4.4460  8.8634  Syn\n1.9_1.425   10.3292 2.6111 18.0473  Syn\n2.85_0.475  13.3296 5.9540 20.7052  Syn\n2.85_0.95   13.3296 7.9390 18.7202  Syn\n2.85_1.425  10.3292 2.6111 18.0473  Syn\n3.8_0.0095   7.7899 0.2695 15.3103  Syn\n3.8_0.0285   7.7899 0.2695 15.3103  Syn\n3.8_0.2375   7.2899 2.9835 11.5963  Syn\n3.8_0.475    7.5613 3.9399 11.1827  Syn\n3.8_0.95     7.7899 4.4820 11.0978  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\nCode\nrsb2 <- fitSurface(caz_gent_kpca2, marginalFit2, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(18,150) = 35.2265 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1     d2      absR p-value call\n1.9_0.95   1.90 0.9500 13.202805  <2e-16  Syn\n1.9_1.425  1.90 1.4250  5.658116  <2e-16  Syn\n1.9_1.9    1.90 1.9000  4.869663   2e-05  Syn\n2.85_0.475 2.85 0.4750  7.867521  <2e-16  Syn\n2.85_0.95  2.85 0.9500 10.492628  <2e-16  Syn\n2.85_1.425 2.85 1.4250  4.577642 0.00013  Syn\n3.8_0.0095 3.80 0.0095  3.809688 0.00379  Syn\n3.8_0.0285 3.80 0.0285  3.809688 0.00379  Syn\n3.8_0.2375 3.80 0.2375  5.933555  <2e-16  Syn\n3.8_0.475  3.80 0.4750  7.822571  <2e-16  Syn\n3.8_0.95   3.80 0.9500  8.960655  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  11   0    18\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.5514 [4.7906, 6.18]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6045 4.4249  8.7841  Syn\n1.9_1.425   10.2930 2.6842 17.9018  Syn\n2.85_0.475  13.3292 6.1146 20.5438  Syn\n2.85_0.95   13.1710 7.9058 18.4361  Syn\n2.85_1.425   9.4954 1.8632 17.1277  Syn\n3.8_0.0095   7.7899 0.5259 15.0539  Syn\n3.8_0.0285   7.7899 0.5259 15.0539  Syn\n3.8_0.2375   7.2899 3.2980 11.2818  Syn\n3.8_0.475    7.5611 4.2940 10.8282  Syn\n3.8_0.95     7.6972 4.7761 10.6183  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\n\n\n\nFigure 23: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 24: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 25: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n3.3.1 Ceftazidime/avibactam plus aztreonam\nResults are shown in ?@fig-12.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_azt <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/ndm_cazavi_azt.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit3 <- fitMarginals(caz_azt, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"AZT\"))\nsummary(marginalFit3)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and aztroenam, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit3) + ggtitle(paste(\"Ceftazidime/Avibactam + Aztreonam\"))\nrs3 <- fitSurface(caz_azt, marginalFit3,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs3)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3082, 10.3485]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1506  2.8494  Syn\n19.95_2.394    7.8025  6.9943  8.6107  Syn\n19.95_3.99    14.5000 13.6645 15.3355  Syn\n19.95_4.9875   9.9250  9.0978 10.7521  Syn\n19.95_7.98    14.5000 13.6316 15.3684  Syn\n19.95_9.975   14.5000 13.6415 15.3585  Syn\n39.9_1.197     3.4999  2.6863  4.3134  Syn\n39.9_19.95    12.3749 11.4706 13.2791  Syn\n39.9_2.394     9.8813  9.0761 10.6865  Syn\n39.9_3.99     14.4999 13.6689 15.3308  Syn\n39.9_39.9     14.4999 13.5223 15.4774  Syn\n39.9_4.9875   11.3429 10.5205 12.1653  Syn\n39.9_7.98     14.4999 13.6364 15.3633  Syn\n39.9_79.8     14.4998 13.4583 15.5414  Syn\n39.9_9.975    14.4999 13.6435 15.3563  Syn\n79.8_19.95    14.4971 13.5630 15.4312  Syn\n79.8_39.9     14.4971 13.5204 15.4738  Syn\n79.8_79.8     14.4970 13.4575 15.5365  Syn\n9.975_1.197    2.2200  1.4120  3.0280  Syn\n9.975_2.394    2.3300  1.4954  3.1646  Syn\n9.975_4.9875   2.7000  1.8453  3.5547  Syn\n9.975_9.975    3.8350  2.9557  4.7143  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\nCode\nplot(rs3, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 26: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\nrsh3 <- fitSurface(caz_azt, marginalFit3,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh3)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(22,32) = 482.777 (p-value < 2e-16)\n\nEvidence for effects in data: Ant\nPoints with significant deviations from the null: \n                 d1      d2      absR p-value call\n19.95_1.197  19.950  1.1970 22.149569  <2e-16  Ant\n19.95_2.394  19.950  2.3940 13.004736  <2e-16  Ant\n19.95_3.99   19.950  3.9900 30.576846  <2e-16  Syn\n19.95_4.9875 19.950  4.9875  4.306253 0.00311  Syn\n19.95_7.98   19.950  7.9800 24.022524  <2e-16  Syn\n19.95_9.975  19.950  9.9750 35.656311  <2e-16  Syn\n39.9_1.197   39.900  1.1970 27.642378  <2e-16  Ant\n39.9_19.95   39.900 19.9500  9.046079  <2e-16  Syn\n39.9_3.99    39.900  3.9900 26.954813  <2e-16  Syn\n39.9_39.9    39.900 39.9000 13.323312  <2e-16  Syn\n39.9_4.9875  39.900  4.9875 11.550743  <2e-16  Syn\n39.9_7.98    39.900  7.9800 21.270610  <2e-16  Syn\n39.9_79.8    39.900 79.8000 10.385527  <2e-16  Syn\n39.9_9.975   39.900  9.9750 27.811309  <2e-16  Syn\n79.8_19.95   79.800 19.9500 11.793525  <2e-16  Syn\n79.8_39.9    79.800 39.9000 10.465298  <2e-16  Syn\n79.8_79.8    79.800 79.8000  7.699994  <2e-16  Syn\n9.975_1.197   9.975  1.1970 35.692823  <2e-16  Ant\n9.975_2.394   9.975  2.3940 29.602031  <2e-16  Ant\n9.975_4.9875  9.975  4.9875 29.154426  <2e-16  Ant\n9.975_9.975   9.975  9.9750 25.180733  <2e-16  Ant\n\nOverall maxR summary:\n Call Syn Ant Total\n  Ant  14   7    22\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3117, 10.3473]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1029  2.8971  Syn\n19.95_2.394    7.8025  6.9606  8.6443  Syn\n19.95_3.99    14.5000 13.6351 15.3649  Syn\n19.95_4.9875   9.9250  9.0743 10.7757  Syn\n19.95_7.98    14.5000 13.6128 15.3872  Syn\n19.95_9.975   14.5000 13.6314 15.3685  Syn\n39.9_1.197     3.4999  2.6341  4.3656  Syn\n39.9_19.95    12.3749 11.4695 13.2802  Syn\n39.9_2.394     9.8813  9.0329 10.7297  Syn\n39.9_3.99     14.4999 13.6300 15.3697  Syn\n39.9_39.9     14.4999 13.5488 15.4510  Syn\n39.9_4.9875   11.3429 10.4872 12.1986  Syn\n39.9_7.98     14.4999 13.6080 15.3917  Syn\n39.9_79.8     14.4999 13.5241 15.4756  Syn\n39.9_9.975    14.4999 13.6229 15.3768  Syn\n79.8_19.95    14.4971 13.5502 15.4439  Syn\n79.8_39.9     14.4971 13.5404 15.4538  Syn\n79.8_79.8     14.4971 13.5187 15.4755  Syn\n9.975_1.197    2.2200  1.3765  3.0635  Syn\n9.975_2.394    2.3300  1.4643  3.1957  Syn\n9.975_4.9875   2.7000  1.8237  3.5763  Syn\n9.975_9.975    3.8350  2.9482  4.7218  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\nCode\nrsb3 <- fitSurface(caz_azt, marginalFit3, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb3)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(22,32) = 508.0207 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n                 d1      d2      absR p-value call\n19.95_1.197  19.950  1.1970 22.458782  <2e-16  Ant\n19.95_2.394  19.950  2.3940 13.484443  <2e-16  Ant\n19.95_3.99   19.950  3.9900 31.413435  <2e-16  Syn\n19.95_4.9875 19.950  4.9875  6.427040  <2e-16  Syn\n19.95_7.98   19.950  7.9800 25.801606  <2e-16  Syn\n19.95_9.975  19.950  9.9750 39.153578  <2e-16  Syn\n39.9_1.197   39.900  1.1970 29.991664  <2e-16  Ant\n39.9_19.95   39.900 19.9500 10.930062  <2e-16  Syn\n39.9_2.394   39.900  2.3940  3.743521 0.01539  Ant\n39.9_3.99    39.900  3.9900 25.716968  <2e-16  Syn\n39.9_39.9    39.900 39.9000 15.759285  <2e-16  Syn\n39.9_4.9875  39.900  4.9875  9.341362  <2e-16  Syn\n39.9_7.98    39.900  7.9800 21.454814  <2e-16  Syn\n39.9_79.8    39.900 79.8000 15.453467  <2e-16  Syn\n39.9_9.975   39.900  9.9750 28.423258  <2e-16  Syn\n79.8_19.95   79.800 19.9500 11.013550  <2e-16  Syn\n79.8_39.9    79.800 39.9000 10.771160  <2e-16  Syn\n79.8_79.8    79.800 79.8000 10.468869  <2e-16  Syn\n9.975_1.197   9.975  1.1970 35.970464  <2e-16  Ant\n9.975_2.394   9.975  2.3940 28.871466  <2e-16  Ant\n9.975_4.9875  9.975  4.9875 27.433089  <2e-16  Ant\n9.975_9.975   9.975  9.9750 22.349685  <2e-16  Ant\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  14   8    22\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3151, 10.3434]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1659  2.8340  Syn\n19.95_2.394    7.8025  7.0454  8.5596  Syn\n19.95_3.99    14.5000 13.7191 15.2809  Syn\n19.95_4.9875   9.9250  9.1649 10.6850  Syn\n19.95_7.98    14.5000 13.6985 15.3015  Syn\n19.95_9.975   14.5000 13.7252 15.2748  Syn\n39.9_1.197     3.4999  2.7044  4.2953  Syn\n39.9_19.95    12.3749 11.5603 13.1894  Syn\n39.9_2.394     9.8813  9.1150 10.6476  Syn\n39.9_3.99     14.4999 13.7118 15.2879  Syn\n39.9_39.9     14.4999 13.6369 15.3628  Syn\n39.9_4.9875   11.3429 10.5755 12.1102  Syn\n39.9_7.98     14.4999 13.6915 15.3082  Syn\n39.9_79.8     14.4998 13.6331 15.3666  Syn\n39.9_9.975    14.4999 13.7132 15.2865  Syn\n79.8_19.95    14.4971 13.6178 15.3763  Syn\n79.8_39.9     14.4971 13.6140 15.3801  Syn\n79.8_79.8     14.4970 13.6105 15.3835  Syn\n9.975_1.197    2.2200  1.4525  2.9875  Syn\n9.975_2.394    2.3300  1.5417  3.1183  Syn\n9.975_4.9875   2.7000  1.9065  3.4935  Syn\n9.975_9.975    3.8350  3.0366  4.6334  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\n\n\n\nFigure 27: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\n3.3.2 Ceftazidime/avibactam plus colistin\nResults are shown in ?@fig-13.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_col <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kpcb_colistin_cazavi.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit4 <- fitMarginals(caz_col, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"COL\"))\nsummary(marginalFit4)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and colistin, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit4) + ggtitle(paste(\"Ceftazidime/Avibactam + Colistin\"))\nrs4 <- fitSurface(caz_col, marginalFit4,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs4)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.9751 [1.0809, 3.1257]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate  lower   upper call\n0.95_0.057     3.0903 0.5076  5.6730  Syn\n0.95_0.11875   4.6662 0.1831  9.1493  Syn\n1.9_0.057      5.0066 0.8011  9.2120  Syn\n1.9_0.11875    6.0052 0.1669 11.8434  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   4   0    10\n\n\nCode\nplot(rs4, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 28: Effect of combined ceftazidime/avibactam and colistin effects on Tpos\n\n\n\nCode\nrsh4 <- fitSurface(caz_col, marginalFit4,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh4)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(10,116) = 10.6972 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2     absR p-value call\n0.95_0.057   0.95 0.05700 5.135618   1e-05  Syn\n0.95_0.11875 0.95 0.11875 4.185532 0.00049  Syn\n1.9_0.057    1.90 0.05700 4.834160   2e-05  Syn\n1.9_0.11875  1.90 0.11875 6.282205  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   4   0    10\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.315 [1.4096, 3.1969]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n0.95_0.057    3.1029 0.0431  6.1627  Syn\n1.9_0.057     5.1054 0.1468 10.0639  Syn\n1.9_0.11875   9.2794 2.3581 16.2006  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   3   0    10\n\n\nCode\nrsb4 <- fitSurface(caz_col, marginalFit4, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb4)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(10,116) = 8.9424 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2     absR p-value call\n0.95_0.057   0.95 0.05700 4.939011  <2e-16  Syn\n0.95_0.11875 0.95 0.11875 4.706784   3e-05  Syn\n1.9_0.057    1.90 0.05700 5.072593  <2e-16  Syn\n1.9_0.11875  1.90 0.11875 4.099764 0.00076  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   4   0    10\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.9751 [0.9216, 3.4088]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n[1] estimate lower    upper    call    \n<0 rows> (or 0-length row.names)\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   0   0    10\n\n\n\n\n\nFigure 29: Effect of combined ceftazidime/avibactam and colistin effects on Tpos\n\n\n\n\n\n\n3.3.3 Ceftazidime/avibactam plus tigecycline\nResults are shown in ?@fig-14.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_tig <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kcb_cazavi_tig.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit5 <- fitMarginals(caz_tig, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"TIG\"))\nsummary(marginalFit5)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and tigecycline, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit5) + ggtitle(paste(\"Ceftazidime/Avibactam + Tigecycline\"))\nrs5 <- fitSurface(caz_tig, marginalFit5,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs5)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.6626 [0.7233, 2.7338]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   1.6400 0.4535 2.8265  Syn\n79.8_9.975   2.3744 1.2413 3.5075  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0     3\n\n\nCode\nplot(rs5, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 30: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos\n\n\n\nCode\nrsh5 <- fitSurface(caz_tig, marginalFit5,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh5)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(3,75) = 4.8073 (p-value = 0.0041)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1    d2    absR p-value call\n79.8_19.95 79.8 19.95 2.75595 0.02189  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   1   0     3\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.704 [1.6392, 3.6561]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   3.5137 2.1299 4.8976  Syn\n79.8_39.9    2.0597 0.6517 3.4676  Syn\n79.8_9.975   2.5387 1.1549 3.9226  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   3   0     3\n\n\nCode\nrsb5 <- fitSurface(caz_tig, marginalFit5, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb5)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(3,75) = 1.8988 (p-value = 0.1371)\nMaxR test did not detect any deviations from the null.\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.6626 [0.6256, 2.5476]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   1.6400 0.3335 2.9466  Syn\n79.8_9.975   2.3744 1.1403 3.6085  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0     3\n\n\n\n\n\nFigure 31: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos"
  },
  {
    "objectID": "Workpackage2.html",
    "href": "Workpackage2.html",
    "title": "Workpackage 2",
    "section": "",
    "text": "Code\nlibrary(PKPDsim)\nlibrary(PKPDplot)\nlibrary (ggplot2)\npk1 <- new_ode_model(model = \"pk_2cmt_iv\") # ceftazidime\npk2 <- new_ode_model(model = \"pk_2cmt_iv\") # avibactam\np <- list(\n  CL = 6.95,\n  V  = 10.5,\n  Q  = 31.5,\n  V2 = 7.57)\n\np2 <- list(\n  CL = 10.2,\n  V  = 11.1,\n  Q  = 5.44,\n  V2 = 6.91)\nn <- 100\n\nomega <- cv_to_omega(list(CL=0.423, V=1.05, Q=0.315, V2=1.10))\n\nomega2 <- cv_to_omega(list(CL=0.591, V=1.07, Q=1.22, V2=6.91))\nr1 <- new_regimen(\n  amt = 2000,\n  interval = 8,\n  n = 5,\n  type = \"infusion\",\n  t_inf = c(2,2,2,2,2)\n)\n\nr2 <- new_regimen(\n  amt = 500,\n  interval = 8,\n  n = 5,\n  type = \"infusion\",\n  t_inf = c(2,2,2,2,2)\n)\ndat <- sim(\n  ode = pk1,\n  parameters = p,\n  omega = omega,\n  n_ind = 20,\n  res_var = list(prop=0.1, add=7.5),\n  regimen = r1, \n  covariates = list(\"SCR\" = new_covariate(value = 80)), output_include = list(parameters=TRUE, variable=TRUE, covariates=TRUE)\n)\n\ndat2 <- sim(\n  ode = pk2,\n  parameters = p2,\n  omega = omega2,\n  n_ind = 20,\n  res_var = list(prop=0.17, add=0.5),\n  regimen = r2, \n  covariates = list(\"SCR\" = new_covariate(value = 80)), output_include = list(parameters=TRUE, variable=TRUE, covariates=TRUE)\n)\n\nplot(dat, show_population = list(obs = TRUE, spaghetti = FALSE, ci = TRUE, \n                                 median =TRUE, regimen = TRUE), ci = c(0.05, 0.95))"
  },
  {
    "objectID": "Presentations.html",
    "href": "Presentations.html",
    "title": "Presentations",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "Timeline.html",
    "href": "Timeline.html",
    "title": "Timeline",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "Protocols.html",
    "href": "Protocols.html",
    "title": "Protocols",
    "section": "",
    "text": "sterile 15 ml falcon tube \nglass tubes\ntube racks\nDensiCHEK plus Biomerieux\nVortex\n100-1000 mcl mechanical pipette\n1 ml sterile insulin syringe\nserum from healthy volunteers\nsaline sterile solution\nMH broth\nBacT/ALERT FA FAN® Aerobic Biomeriuex blood culture bottles\nBacT/ALERT SA Standard Aerobic Biomerieux blood culture bottles (without inactivating matrix)\nBact/ALERT 3D Biomerieux incubator system\n\n\n\n\n\nBacterial strains were obtained from the banked collection of the Microbiology Unit, Hub Laboratory, AUSL Romagna, Cesena, Italy.\nEach day before testing, strains are thawed and incubated at 37°C for 18-24 hours.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIsolate\nAbbreviation\nEnzyme\nSource\nCeftazidime/Avibactam MIC (mg/L)\nGentamicin\nMeropenem\nMeropenem-Vaborbactam\nColistin\n\n\n\n\nKlebsiella pneumoniae ESBL ATCC 700603\nKP_ATCC\nbla SHV-18\nReference strain\nMIC needed\n\n\n\n\n\n\nKlebsiella pneumoniae KPC- A\nKPC_A\nKPC-3\nClinical isolate\n2\n\n\n\n\n\n\nKlebsiella pneumoniae KPC- B\nKPC_B\nKPC-3\nClinical isolate\n1\n\n\n\n\n\n\nKlebsiella pneumoniae KPC- C\nKPC_C\nKPC-3\nClinical isolate\n\n\n\n\n\n\n\nKlebsiella pneumoniae NDM\nNDM\nNDM-2\nClinical isolate\n>256\n\n\n\n\n\n\nKlebsiella pneumonia VIM\nVIM\nVIM\nClinical isolate\n>256\n\n\n\n\n\n\n\nMICs were performed and confirmed by Etest\n\n\n\nThe proposed method are a modification of Tpos assay as proposed by Kaltsas et al.\nDilution schemes are from the Clinical Laboratory Standards Institute (CLSI) M21-A Methodology for the Serum Bactericidal Test and M26A Methodology for Determining Bactericidal Activity of Antibiotics.\nTo prepare a standardized inoculum (1.5 x102 CFU/mL) for injection in blood culture bottles:\n\nColonies are selected from an 18- to 24-hour agar plate and suspended in sterile 0.9% phosphate buffered saline (PBS) in a glass test tube. The suspension is then adjusted by optimal density using a Densichek turbidity meter to an equivalent to a 0.5 McFarland standard corresponding to 1 to 2 × 108 CFU/mL.\nThe inoculum is then serially diluted using ten-fold dilution scheme: 200 μL inoculum dispensed by micropipette into 1800 μL 0.9% saline → vortexed → then 200 μL of this suspension is pipetted into a fresh tube containing 1800 μL 0.9% saline, etc.) until a final inoculum of 1.5 x102 CFU/ml is reached.\n\nNote the final dilution step is repeated an additional 5 times in replicate tubes to ensure 6 tubes (12 mL of the final 1.5 x102 CFU/mL) are available to inoculate 10 blood culture bottles.\n\n\n\n\n\nAnalytical grade (> 99% pure) ceftazidime (200 μg/mL) and avibactam (500 μg/mL) pure powder are diluted separately in sterile water to prepare a stock solution of ceftazidime (200 μg/mL) and avibactam (500 μg/mL). The stock solution is dispensed into 2 mL sterile cryo-vials and stored at -20°C.\nFrozen stock antibiotic solution in cryo-vials is thawed the day of the experiment and diluted at twice the final test concentration using either (a) pooled patient serum; or (b) 0.9% PBS.\n\nExample: to obtain 2 mL of 20 mcg/ml stock: 200 μL of ceftazidime 200 mg/mL solution is pipetted into a test-tube containing 1800 μL of serum\nExample to obtain 50 μg/mL: using the multipipettor set at 500 μL, 500 μL of ceftazidime 200 μg/ml solution are added in a tube containing 1500 μL of serum\n500 μL of the ceftazidime 2x concentration and 500 μL of the 2x avibactam concentration are then added in a test tube to obtain 1 ml of serum-antibiotic solution at the desired concentrations\n\nAfter vortexing for 7-10 seconds each tube, 1 ml of inoculum suspension at 1.5x102 CFU/mL and 1 mL of antibiotic containing serum are inoculated with a sterile insulin syringe into a blood culture bottle containing 40 mL of enrichment broth without inactivating matrix.\nBloodculture bottles are then incubated into Bact/ALERT system to detect growth. The same procedure is repeated for all the selected antibiotic concentration-inoculum pairs.\nOne bottle is inoculated with the bacterial inoculum without adding the antibiotic solution (drug-free control).\ndescribe incubation conditions, incubator settings, etc. \nhow are data collected from the software etc."
  }
]